Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 540

• Price / Volume Information    Yesterday's Closing Price: $33.10 Daily Weekly Monthly 20 Day Moving Average: 843,182 shares Shares Outstanding: 59.70 (millions) Market Capitalization: $1,976.13 (millions) Beta: 0.60 52 Week High: $46.00 52 Week Low: $22.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.56% 2.02% 12 Week 4.02% 1.81% Year To Date 21.60% 7.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - morgan.sanford@agios.com http://www.agios.com

• General Corporate Information    Officers Brian Goff - ChiefExecutiveOfficer Jacqualyn A. Fouse - Chair of the Board of Directors Cecilia Jones - Chief Financial Officer T.J. Washburn - Vice President; Controller Jay Backstrom - Director Peer Information Agios Pharmaceuticals, Inc. (CORR.) Agios Pharmaceuticals, Inc. (RSPI) Agios Pharmaceuticals, Inc. (CGXP) Agios Pharmaceuticals, Inc. (BGEN) Agios Pharmaceuticals, Inc. (GTBP) Agios Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 10/29/26 Share - Related Items Shares Outstanding: 59.70 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $1,976.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 33.22% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.93 Price/Cash Flow: - Price / Sales: 20.10 EPS Growth vs. Year Ago Period: 12.44% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 259.25% vs. Previous Quarter: 115.68% ROE 06/30/26 - -35.67 03/31/26 - -34.11 12/31/25 - -31.07 ROA 06/30/26 - -33.06 03/31/26 - -31.66 12/31/25 - -28.92 Current Ratio 06/30/26 - 10.22 03/31/26 - 14.19 12/31/25 - 11.46 Quick Ratio 06/30/26 - 9.79 03/31/26 - 13.59 12/31/25 - 11.06 Operating Margin 06/30/26 - -418.24 03/31/26 - -639.84 12/31/25 - -764.01 Net Margin 06/30/26 - -418.24 03/31/26 - -639.84 12/31/25 - -764.01 Pre-Tax Margin 06/30/26 - -419.27 03/31/26 - -641.38 12/31/25 - -765.89 Book Value 06/30/26 - 17.19 03/31/26 - 18.65 12/31/25 - 20.46 Inventory Turnover 06/30/26 - 0.24 03/31/26 - 0.20 12/31/25 - 0.20 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©